Cancer Oncologic Drugs Between us Food and Drug Administration
Received Date: Jul 01, 2023 / Published Date: Jul 31, 2023
Abstract
Cancer drug prices are rising faster than the prices in other sectors of health care, drawing concern from patients,physicians, and policy researchers. We found little difference in the median wholesale price of 21 novel drugs and 30 next-in-class drugs approved over a 5-yearperiod. Our results suggest that the price of cancer drugs is independent of novelty. Additionally, we found little difference in price among drugs approved based on time-to-event end points and drugs approved on the basis of RR. Our results suggest that current pricing models are not rational but simply reflect what the market will bear.
Keywords: High-risk research; Canadian data; Cancer treatment; Treatment options; Patient utilities; Total benefits
Citation: Hsu GC (2023) Cancer Oncologic Drugs Between us Food and DrugAdministration. Adv Cancer Prev 7: 179. Doi: 10.4172/2472-0429.1000179
Copyright: © 2023 Hsu GC. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Tools
Article Usage
- Total views: 271
- [From(publication date): 0-2023 - May 20, 2024]
- Breakdown by view type
- HTML page views: 230
- PDF downloads: 41
